- Home
- ORIC vs EU Comparison
ORIC vs EU Comparison
Compare ORIC & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | EU |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 306.9M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ORIC | EU |
|---|---|---|
| Price | $12.70 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $19.73 | $4.00 |
| AVG Volume (30 Days) | 1.1M | ★ 6.0M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | 11.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $43,155,000.00 |
| Revenue This Year | N/A | $212.11 |
| Revenue Next Year | N/A | $29.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.23 | $0.77 |
| 52 Week High | $14.93 | $4.19 |
Technical Indicators
Market Signals| Indicator | ORIC | EU |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 34.99 |
| Support Level | $10.67 | N/A |
| Resistance Level | $13.04 | $1.47 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 50.00 | 26.72 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.